22nd Century Group Inc. is a biotechnology company specializing in the genetic engineering of tobacco and cannabis plants. The company's primary function is to develop plant varieties with modified levels of nicotine and cannabinoid profiles, aiming to meet evolving consumer and regulatory demands. A key feature of 22nd Century Group Inc. is its focus on creating low-nicotine tobacco products and hemp/cannabis plants with specific cannabinoid contents. These innovations have significant implications for the agricultural biotechnology sector and public health policy discussions regarding tobacco harm reduction. By leveraging its proprietary genetic technologies and collaborations, the company positions itself as a leader in altering plant alkaloid content to enhance product offerings and create potentially safer tobacco alternatives. Headquartered in the United States, 22nd Century Group Inc. plays a strategic role in both the tobacco and cannabis industries, addressing the growing need for reduced-risk products while exploring the vast potential of cannabinoid applications. Its contributions reflect broader trends in biotechnology, agriculture, and consumer health advocacy, making it a company of interest in these intersecting fields.